Identification of a novel chemical potentiator and inhibitors of UCH-L1 by in silico drug screening

Neurochemistry International

Volumn 56, Issue 5, 2010, Pages 679-686

  Mitsui, Takeshi ^a,b   Hirayama, Kazunori ^a,b   Aoki, Shunsuke ^a,c   Nishikawa, Kaori ^a   Uchida, Kenko ^b   Matsumoto, Takashi ^b   Kabuta, Tomohiro ^a   Wada, Keiji ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b WASEDA UNIVERSITY   (Japan)

^c KYUSHU INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Alzheimer's disease; Cancer; In silico; Inhibitor; Potentiator; Ubiquitin C terminal hydrolase L1 (UCH L1)

Indexed keywords

1 (1,3 BENZODIOXOL 5 YLMETHYL) 4 [4 [[(4 CHLOROPHENYL)THIO]METHYL]BENZOYL]PIPERAZINE; 1 (4 METHOXYPHENYL) 4 [[3 (4 METHOXYPHENYL) 1,2,4 OXADIAZOL 5 YL]METHYL]PIPERAZINE; 2 [(5 ETHYL 5H [1,2,4]TRIAZINO(5,6 B)INDOL 3 YL)THIO] N (4 METHYL 2 PYRIDINYL)ACETAMIDE; 2 [[4 (2 FURYLMETHYL) 5 (2 THIENYLMETHYL) 4H 1,2,4 TRIAZOL 3 YL]THIO] N (2 METHOXYDIBENZO[B,D]FURAN 3 YL)ACETAMIDE; 3 METHYL 8 (4METHYL 1 PIPERAZINYL) 7 (3 PHENYLPROPYL) 3,7 DIHYDRO 1H PURINE 2,6 DIONE; 4 [[BENZYL(METHYL)AMINO]SULFONYL] N [5 (BENZYLTHIO) 1,3,4 THIADAZOL 2 YL]BENZAMIDE; 8 [(1H BENZIMIDAZOL 2 YLMETHYL)THIOL] 2,2 DIMETHYL 5 (MORPHOLINYL) 1,4 DIHYDRO 2H PYRANOL[4'',3'':4',5']PYRIDOL[3',2':4,5]THIENO[3,2 D]PYRIMIDINE; ENZYME ACTIVATOR; ENZYME INHIBITOR; ETHYL 1 [N (4 METHYLPHENYL) N (METHYLSULFONYL)ALANYL] 4 PIPERIDINECARBOXYLATE; HYDROLASE; N (3,6 DICHLORO 2 PYRIDINYL) N' [[(4,6 DIPHENYL 2 PYRIMIDINYL)AMINO]CARBONYL]SULFAMIDE; N 1,3 BENZOTHIAZOL 2 YL 2 [[5 (4 MORPHOLINYLMETHYL) 4 PHENYL 4H 1,2,4 TRIAZOL 3 YL]THIO]ACETAMIDE; N [2 (4 BENZYL 1 PIPERAZINYL) 2 OXOETHYL] N (3 METHYLPHENYL)BENZENESULFONAMIDE; N [2 [(6,7 DIMETHOXY 1 ISOQUINOLINYL)METHYL] 4,5 DIMETHOXYPHENYL] 4 (2 OXO 1 PYRROLIDINYL)BENZENESULFONAMIDE; N [4 [[(4 ETHOXYPHENYL)AMINO]SULFONYL]PHENYL] 2 NAPHTHALENESULFONAMIDE; N [4 [[(4 METHYLPHENYL)AMINO]SULFONYL]PHENYL] 2 PHENYL 2 (PHENYLTHIO)ACETAMIDE; N [6 [[2[(4 CHLOROPHENYL)THIO]ACETYL]AMINO] 1,3 BENZOTHIAZOL 2 YL]BUTANAMIDE; N,N' (OXYDI 4,1 PHENYLENE)DIBENZENESULFONAMIDE; N,N' 4,4' BIPHENYLDIYLBIS(4 ETHYLBENZENESULFONAMIDE); N1 CYLOPROPYL N2 (4 ETHOXYPHENYL) N2 [(4 METHYLPHENYL)SULFONYL]GLYCINAMIDE; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

ARTICLE; COMPUTER MODEL; CRYSTAL STRUCTURE; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BINDING; ENZYME INHIBITION; PRIORITY JOURNAL;

COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GENE LIBRARY; HUMANS; INDICATORS AND REAGENTS; INHIBITORY CONCENTRATION 50; KINETICS; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; UBIQUITIN THIOLESTERASE;

EID: 77949570178     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.01.016     Document Type: Article

References (37)

1. Carmine Belin A., Westerlund M., Bergman O., Nissbrandt H., Lind C., Sydow O., Galter D. S18Y in ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) associated with decreased risk of Parkinson's disease in Sweden. Parkinsonism Relat. Disord. 2007, 13:295-298.
2. Choi J., Levey A.I., Weintraub S.T., Rees H.D., Gearing M., Chin L.S., Li L. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 2004, 279:13256-13264.
3. Das C., Hoang Q.Q., Kreinbring C.A., Luchansky S.J., Meray R.K., Ray S.S., Lansbury P.T., Ringe D., Petsko G.A. Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:4675-4680.
4. Elbaz A., Levecque C., Clavel J., Vidal J.S., Richard F., Correze J.R., Delemotte B., Amouyel P., Alperovitch A., Chartier-Harlin M.C., Tzourio C. S18Y polymorphism in the UCH-L1 gene and Parkinson's disease: evidence for an age-dependent relationship. Mov. Disord. 2003, 18:130-137.
5. Giambanco I., Bianchi R., Ceccarelli P., Pula G., Sorci G., Antonioli S., Bocchini V., Donato R. 'Neuron-specific' protein gene product 9.5 (PGP 9.5) is also expressed in glioma cell lines and its expression depends on cellular growth state. FEBS Lett. 1991, 290:131-134.
6. Gong B., Cao Z., Zheng P., Vitolo O.V., Liu S., Staniszewski A., Moolman D., Zhang H., Shelanski M., Arancio O. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 2006, 126:775-788.
7. Hendlich M., Rippmann F., Barnickel G. LIGSITE: automatic and efficient detection of potential small molecule-binding sites in proteins. J. Mol. Graph. Model. 1997, 15:359-363.
8. Hibi K., Westra W.H., Borges M., Goodman S., Sidransky D., Jen J. PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am. J. Pathol. 1999, 155:711-715.
9. Hirayama K., Aoki S., Nishikawa K., Matsumoto T., Wada K. Identification of novel chemical inhibitors for ubiquitin C-terminal hydrolase-L3 by virtual screening. Bioorg. Med. Chem. 2007, 15:6810-6818.
10. Howell V.M., Gill A., Clarkson A., Nelson A.E., Dunne R., Delbridge L.W., Robinson B.G., Teh B.T., Gimm O., Marsh D.J. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J. Clin. Endocrinol. Metab. 2009, 94:434-441.
11. Johnston S.C., Larsen C.N., Cook W.J., Wilkinson K.D., Hill C.P. Crystal structure of a deubiquitinating enzyme (human UCH-L3) at 1.8A resolution. EMBO J. 1997, 16:3787-3796.
12. Kabuta T., Wada K. Insights into links between familial and sporadic Parkinson's disease: physical relationship between UCH-L1 variants and chaperone-mediated autophagy. Autophagy 2008, 4:827-829.
13. Kabuta T., Furuta A., Aoki S., Furuta K., Wada K. Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy. J. Biol. Chem. 2008, 283:23731-23738.
14. Kabuta T., Setsuie R., Mitsui T., Kinugawa A., Sakurai M., Aoki S., Uchida K., Wada K. Aberrant molecular properties shared by familial Parkinson's disease-associated mutant UCH-L1 and carbonyl-modified UCH-L1. Hum. Mol. Genet. 2008, 17:1482-1496.
15. Kim H.J., Kim Y.M., Lim S., Nam Y.K., Jeong J., Kim H.J., Lee K.J. Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene 2009, 28:117-127.
16. Kwon J., Wang Y.L., Setsuie R., Sekiguchi S., Sakurai M., Sato Y., Lee W.W., Ishii Y., Kyuwa S., Noda M., Wada K., Yoshikawa Y. Developmental regulation of ubiquitin C-terminal hydrolase isozyme expression during spermatogenesis in mice. Biol. Reprod. 2004, 71:515-521.
17. Larsen C.N., Krantz B.A., Wilkinson K.D. Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry 1998, 37:3358-3368.
18. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature 1998, 395:451-452.
19. Liu Y., Fallon L., Lashuel H.A., Liu Z., Lansbury P.T. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 2002, 111:209-218.
20. Liu Y., Lashuel H.A., Choi S., Xing X., Case A., Ni J., Yeh L.A., Cuny G.D., Stein R.L., Lansbury P.T. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem. Biol. 2003, 10:837-846.
21. Maraganore D.M., Farrer M.J., Hardy J.A., Lincoln S.J., McDonnell S.K., Rocca W.A. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 1999, 53:1858-1860.
22. Maraganore D.M., Lesnick T.G., Elbaz A., Chartier-Harlin M.C., Gasser T., Kruger R., Hattori N., Mellick G.D., Quattrone A., Satoh J., Toda T., Wang J., Ioannidis J.P., de Andrade M., Rocca W.A. UCHL1 is a Parkinson's disease susceptibility gene. Ann. Neurol. 2004, 55:512-521.
23. Misaghi S., Galardy P.J., Meester W.J., Ovaa H., Ploegh H.L., Gaudet R. Structure of the ubiquitin hydrolase UCH-L3 complexed with a suicide substrate. J. Biol. Chem. 2005, 280:1512-1520.
24. Miyoshi Y., Nakayama S., Torikoshi Y., Tanaka S., Ishihara H., Taguchi T., Tamaki Y., Noguchi S. High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer. Cancer Sci. 2006, 97:523-529.
25. Momose Y., Murata M., Kobayashi K., Tachikawa M., Nakabayashi Y., Kanazawa I., Toda T. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann. Neurol. 2002, 51:133-136.
26. Nishikawa K., Li H., Kawamura R., Osaka H., Wang Y.L., Hara Y., Hirokawa T., Manago Y., Amano T., Noda M., Aoki S., Wada K. Alterations of structure and hydrolase activity of Parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem. Biophys. Res. Commun. 2003, 304:176-183.
27. Osaka H., Wang Y.L., Takada K., Takizawa S., Setsuie R., Li H., Sato Y., Nishikawa K., Sun Y.J., Sakurai M., Harada T., Hara Y., Kimura I., Chiba S., Namikawa K., Kiyama H., Noda M., Aoki S., Wada K. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum. Mol. Genet. 2003, 12:1945-1958.
28. Rolen U., Kobzeva V., Gasparjan N., Ovaa H., Winberg G., Kisseljov F., Masucci M.G. Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol. Carcinog. 2006, 45:260-269.
29. Rolen U., Freda E., Xie J., Pfirmann T., Frisan T., Masucci M.G. The ubiquitin C-terminal hydrolase UCH-L1 regulates B-cell proliferation and integrin activation. J. Cell Mol. Med. 2008, 10.1111/j.1582-4934.2008.00501.x.
30. Sakurai M., Sekiguchi M., Zushida K., Yamada K., Nagamine S., Kabuta T., Wada K. Reduction in memory in passive avoidance learning, exploratory behaviour and synaptic plasticity in mice with a spontaneous deletion in the ubiquitin C-terminal hydrolase L1 gene. Eur. J. Neurosci. 2008, 27:691-701.
31. Sekiguchi S., Kwon J., Yoshida E., Hamasaki H., Ichinose S., Hideshima M., Kuraoka M., Takahashi A., Ishii Y., Kyuwa S., Wada K., Yoshikawa Y. Localization of ubiquitin C-terminal hydrolase L1 in mouse ova and its function in the plasma membrane to block polyspermy. Am. J. Pathol. 2006, 169:1722-1729.
32. Takase T., Hibi K., Yamazaki T., Nakayama H., Taguchi M., Kasai Y., Ito K., Akiyama S., Nagasaka T., Nakao A. PGP9.5 overexpression in esophageal squamous cell carcinoma. Hepatogastroenterology 2003, 50:1278-1280.
33. Tezel E., Hibi K., Nagasaka T., Nakao A. PGP9.5 as a prognostic factor in pancreatic cancer. Clin. Cancer Res. 2000, 6:4764-4767.
34. Wang J., Zhao C.Y., Si Y.M., Liu Z.L., Chen B., Yu L. ACT and UCH-L1 polymorphisms in Parkinson's disease and age of onset. Mov. Disord. 2002, 17:767-771.
35. Wilkinson K.D., Lee K.M., Deshpande S., Duerksen-Hughes P., Boss J.M., Pohl J. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 1989, 246:670-673.
36. Xue S., Jia J. Genetic association between ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism and sporadic Alzheimer's disease in a Chinese Han population. Brain Res. 2006, 1087:28-32.
37. Yamazaki T., Hibi K., Takase T., Tezel E., Nakayama H., Kasai Y., Ito K., Akiyama S., Nagasaka T., Nakao A. PGP9.5 as a marker for invasive colorectal cancer. Clin. Cancer Res. 2002, 8:192-195.